pristinamycin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
antibiotics, produced by Streptomyces strains 3489 270076-60-3

Description:

MoleculeDescription

Synonyms:

  • pristinamycine
  • pristinamycin
An antibiotic mixture originally isolated from Streptomyces pristinaspiralis. It is a mixture of compounds from STREPTOGRAMIN GROUP A: pristinamycin IIA and IIB and from STREPTOGRAMIN GROUP B: pristinamycin IA, pristinamycin IB, pristinamycin IC.
  • Molecular weight: 1349.51
  • Formula: C71H84N10O17
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA: 224.72
  • ALOGS:
  • ROTB: None

Drug dosage:

DoseUnitRoute
2 g O

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

None

Approvals:

None

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Acute kidney injury 131.90 39.79 82 1806 320305 90306254
Drug reaction with eosinophilia and systemic symptoms 125.07 39.79 43 1845 42715 90583844
Hepatocellular injury 112.14 39.79 36 1852 28922 90597637
Rash maculo-papular 111.33 39.79 39 1849 40894 90585665
Cholestasis 92.64 39.79 33 1855 36266 90590293
Acute generalised exanthematous pustulosis 87.26 39.79 25 1863 13678 90612881
Dermatitis exfoliative generalised 83.13 39.79 20 1868 5573 90620986
Lactic acidosis 65.15 39.79 28 1860 50435 90576124
Hyponatraemia 54.15 39.79 34 1854 133504 90493055
Hyperkalaemia 49.41 39.79 25 1863 64939 90561620

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Pancreatitis acute 60.37 42.52 24 922 33540 42586849
Urethritis mycoplasmal 58.33 42.52 7 939 21 42620368

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Acute kidney injury 159.24 33.05 126 2492 635304 109951377
Hepatocellular injury 138.19 33.05 50 2568 50592 110536089
Rash maculo-papular 129.81 33.05 53 2565 74169 110512512
Acute generalised exanthematous pustulosis 113.55 33.05 35 2583 21629 110565052
Drug reaction with eosinophilia and systemic symptoms 105.06 33.05 47 2571 82048 110504633
Cholestasis 95.72 33.05 41 2577 64477 110522204
Lactic acidosis 69.91 33.05 37 2581 92774 110493907
Dermatitis exfoliative generalised 67.21 33.05 20 2598 10952 110575729
Urethritis mycoplasmal 57.86 33.05 7 2611 21 110586660
Pancreatitis acute 56.91 33.05 28 2590 60246 110526435
Toxic skin eruption 56.17 33.05 22 2596 27493 110559188
Eosinophilia 51.98 33.05 26 2592 57910 110528771
Hyponatraemia 45.31 33.05 39 2579 217614 110369067
Fixed eruption 40.81 33.05 11 2607 4221 110582460
Hyperkalaemia 38.13 33.05 29 2589 135767 110450914
Myoglobin blood increased 36.15 33.05 10 2608 4222 110582459
Erythema 35.65 33.05 39 2579 291408 110295273

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC J01FG01 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIBACTERIALS FOR SYSTEMIC USE
MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS
Streptogramins
MeSH PA D000890 Anti-Infective Agents
MeSH PA D000900 Anti-Bacterial Agents
CHEBI has role CHEBI:33281 antimicrobial agent
CHEBI has role CHEBI:36047 antibacterial drug
CHEBI has role CHEBI:76969 bacterial metabolite

Related Drugs by ATC class:

J01FG Streptogramins 2 drugs
dalfopristinquinupristin

Drug Use | Suggest Off label Use Form| |View source of the data|

None




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

IDSource
N0000170360 NUI
C1148067 UMLSCUI
CHEBI:85274 CHEBI
D025762 MESH_DESCRIPTOR_UI
DB13704 DRUGBANK_ID
1258 INN_ID
4O8O7Q7IU4 UNII
11979535 PUBCHEM_CID
66958 RXNORM
005720 NDDF
16324611000001108 SNOMEDCT_US

Pharmaceutical products:

None